$ORIC Q4 2025 Earnings Preview: Analysis of Recent Insider Trading and Hedge Fund Activity

$ORIC ($ORIC) is set to announce its quarterly financial results on Monday, February 16th after the market closes, according to Finnhub. Analysts are anticipating zero revenue and earnings of -$0.37 per share. To keep track of insider trading, hedge fund activity, and other details related to $ORIC, one can visit Quiver Quantitative’s $ORIC stock page.

Looking at recent insider trading activity for $ORIC stock, in the last six months, insiders have engaged in ten transactions. Out of these trades, there have been no purchases and ten sales. Among the notable transactions, JACOB CHACKO (PRESIDENT AND CEO) has sold 283,374 shares for approximately $3,167,380, while DOMINIC PISCITELLI (Chief Financial Officer) sold 21,720 shares for an estimated $256,846. Additionally, PRATIK S MULTANI (Chief Medical Officer) and RICHARD A. HEYMAN have also been involved in selling $ORIC shares.

For those interested in monitoring hedge fund activity concerning $ORIC, there have been 85 institutional investors increasing their holdings in $ORIC stock while 70 have decreased their positions in the most recent quarter. Some significant moves include ECOR1 CAPITAL, LLC adding 5,110,048 shares to their portfolio and ORBIMED ADVISORS LLC adding 2,742,475 shares in the previous quarter. On the other hand, FRAZIER LIFE SCIENCES MANAGEMENT, L.P. removed 1,065,334 shares from their portfolio. To gain further insights into hedge funds’ stock portfolios, individuals can refer to Quiver Quantitative’s institutional holdings dashboard.

Wall Street analysts have provided several reports on $ORIC recently, with six firms issuing buy ratings on the stock and none issuing sell ratings. Notable ratings include “Outperform” from Evercore ISI Group, “Overweight” from JP Morgan, and “Buy” from Citigroup. Moreover, analysts have offered price targets for $ORIC, with a median target of $20.0. Analysts like David Nierengarten from Wedbush and Kelsey Goodwin from Piper Sandler have set target prices for $ORIC shares.

It’s essential to note that any information provided here should not be considered financial advice. Potential inaccuracies may exist due to errors in ticker-mapping and other anomalies. To access more details and disclaimers related to $ORIC, individuals can refer to Quiver Quantitative’s platform for comprehensive information.